(Total Views: 569)
Posted On: 04/13/2023 5:48:15 PM
Post# of 148891
Re: biloxiblues #134114
Blocking alpha-synuclein has no effect on Parkinson's disease. Like amyloid beta in Alzheimer's it's unlikely to be the primary cause but a marker of underlying pathologies.
It should come as no surprise to anyone here that the commonality between Parkinson's, Alzheimer's and a host of other neurological disorders is a disregulated immune system which is a specialty of leronlimab. We can only hope that the FDA will wake the hell up and do it's job of saving and improving lives.
It should come as no surprise to anyone here that the commonality between Parkinson's, Alzheimer's and a host of other neurological disorders is a disregulated immune system which is a specialty of leronlimab. We can only hope that the FDA will wake the hell up and do it's job of saving and improving lives.
Quote:
A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson's disease
This significant overlap was further condensed to just 24 biological groups, of which the two with the strongest evidence for association highlight processes involving the immune system. Based on their proposed functions, we have termed these two biological groups the regulation of leucocyte/lymphocyte activity and cytokine-mediated signalling.
The strongest findings from our study show a striking enrichment of genes associated with PD being involved in biological processes related to the immune system. Specifically, these were identified as two distinct but overlapping biological groups related to the regulation of leucocyte/lymphocyte activity and cytokine-mediated signalling. Despite PD not typically being considered an immune disease, there are emerging data that are starting to demonstrate a relationship between PD progression and the immune response.
There is also evidence that altered immune components are coupled with PD progression. For example, CD4 - and CD3-positive T-cells have been found in the substantia nigra and Lewy body lesions of PD patients, respectively, and several inflammatory cytokines such as IL1-beta, IL8, IL6, IL4, TNF-alpha, IFN-gamma are up-regulated in the CSF and sera of PD patients (39,40). LRRK2 has also been shown to regulate B2-lymphocyte function (41), potentially providing a direct link between cell-mediated immunity and PD pathology.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3561909/
(16)
(0)Scroll down for more posts ▼
